help_outline Skip to main content
Add Me To Your Mailing List
Shopping Cart
cancel
HomeEventsNTSPP Presents 4th Thursday CME Program

Events - Event View

This is the "Event Detail" view, showing all available information for this event. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

NTSPP Presents 4th Thursday CME Program

When:
Thursday, September 22, 2022, 7:00 PM until 8:30 PM
Additional Info:
Category:
Seminars
Registration is not Required
Payment In Full In Advance Only

                                                                                         

 

DPC  &  NTSPP

Present

 

Title: “NOVEL SYNTHETIC OPIOIDS: FENTANYL AND BEYOND ”

Presenter(s):   Vecheslav Fedorchenco, MD 

Date/Time:   September 22 , 2022  7:00 - 8:30 PM Central Time

Location:   Virtual via Zoom, from Dallas

Credit Hours:   1.5

 

Workshop Description: One of the main goals of novel psychoactive substances is to bypass the legal restrictions and as such to avoid the label "illicit." In this context fentanyl, a synthetically derived opioid, has gained notoriety in recent years as a substitute to heroin and prescription opioids. Its derivatives as well as non-fentanyl-related compounds that act as opioid agonists are increasingly being recognized in lab samples. While the use of opioids other than fentanyl  is rare and limited, some of these non-fentanyl-related compounds  might have a potential to become a larger issue in the ever changing world of illicit drug use. This presentation aims to discuss the latest trends in fentanyl use, its epidemiology, its relation to overdose death, and the clinical significance of fentanyl as well as other non-fentanyl-related synthetic opioid compounds.  

 

Learning Objectives: After attending this session, participants should be able to:

1)  Describe main trends in fentanyl use

2)  Summarize clinical data available up to date regarding synthetic opioids such as fentanyl

 

Literature References:

1)Weaver, M.F., Hopper, J.A. & Gunderson,E.W. Designer drugs 2015:assessment and management.

Addict Sci Clin Pract 10, 8 (2015).https://doi.org/10.1186/s13722-015-0024-7

2) Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for

Treatment. Neurosci Biobehav Rev. 2019;106:49-57. doi:10.1016/j.neubiorev.2018.12.005

3) Moss, R.B., Carlo, D.J. Higher doses of naloxone are needed in the synthetic opioid era. Subst

Abuse Treat Prev Policy 14, 6 (2019). https://doi.org/10.1186/s13011-019-0195-444 

4) Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons

with opioid use disorder. Drug Alcohol Depend. 2020;214:108147. doi:10.1016/j.drugalcdep. 2020. 108147

5) Miliano C, Margiani G, Fattore L, De Luca MA. Sales and Advertising Channels of New

Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps. Brain Sci. 

2018;8(7):123. Published 2018 Jun 29. doi:10.3390/brainsci807012

REGISTER NOW!

Continuing Medical Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Psychoanalytic Association (APsaA) and The Dallas Psychoanalytic Center (DPC). APsaA is accredited by the ACCME to provide continuing medical education for physicians. The American Psychoanalytic Association designates this Live Activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


IMPORTANT DISCLOSURE INFORMATION FOR ALL LEARNERS: None of the planners and presenters for this educational activity have relevant financial relationship(s)* to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. *Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. -Updated July 2021-

 


Dallas Psychoanalytic Center
PO Box 670218 | Dallas, Texas | 75367-0218
Phone: 214-471-5524
dallaspsychoanalyticcenter@gmail.com